research alliance
Tempus, AstraZeneca Collaborate on Response Biomarker Discovery for Small Cell Lung Cancer
This clinical study, called Sculptor, is the first research to emerge from a strategic collaboration between the companies on oncology therapeutics.
Envisagenics, Bristol Myers Squibb Partner to ID Cancer Therapy Alternative Splice Targets
Envisagenics will use its SpliceCore platform to identify alternative splicing-derived therapeutic targets for BMS's cancer pipeline.
Owkin, Stanford Medicine Collaborate on AI-Driven Lung Cancer, Mesothelioma Biomarker Discovery
The French bioinformatics firm will analyze molecular and other multimodal data in search of new cancer therapeutics.
Metabolon, Parkinson's UK Form Biomarker Discovery Alliance
Metabolon will participate in a Parkinson's UK-funded study to map metabolic changes in serum that can serve as biomarkers of disease progression.
St. Jude, Broad Institute, Dana-Farber Partner to Advance Pediatric Cancer Research
The institutions have invested $60 million into the Pediatric Cancer Dependencies Accelerator to study cancer vulnerabilities and develop treatments.